Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for the cytosine methylation detection in a DNA sample, comprising the following steps:

    a) a genomic DNA sample is treated in a manner capable of distinguishing methylated from unmethylated cytosine bases;

    b) the pre-treated DNA is amplified using at least one oligonucleotide primer, a polymerase and a set of nucleotides of which at least one is marked with a first type of label;

    c) a sequence-specific oligonucleotide or oligomer probe is hybridized to the amplification product and a fluorescence resonance energy transfer (FRET) occurs if the oligonucleotide or oligomer probe, marked with a second type of label, binds in close proximity to one of the labeled nucleotides that was incorporated into the amplification product;

    d) the level of methylation of the sample is determined by the level of interaction between said first and second type of label.

2. (Original) A method according to claim 1, characterised in that the first type of label is a donor fluorophore and the second type of label is an acceptor fluorophore and that the extent of fluorescence resonance energy transfer (FRET) is measured.

3. (Original) A method according to claim 1, characterised in that the first type of label is an acceptor fluorophore and the second type of label is a donor fluorophore and that the extent of fluorescence resonance energy transfer (FRET) is measured.

4. (Original) A method according to claim 1, characterised in that the nucleotides of step b) contain a fluorescent moiety and the probe in step c) a quencher moiety.

5. (Original) A method according to claim 1, characterised in that the nucleotides of step b) contain a quencher moiety and the probe in step c) a fluorescent moiety.

6. (Original) A method according to claim 1, characterised in that the polymerase has no 5' to 3' exonuclease activity in order to prevent degradation of the probe.

7. (Original) A method according to claim 1, characterized in that a change in fluorescence intensity is monitored in real-time during the amplification reaction.

8. (Original) A method according to claim 1, characterized in that a change in fluorescence intensity is monitored at end-point of target amplification.

9. (Previously presented) A method according to claim 1, characterized in that the amplification reaction is achieved with the polymerase chain reaction (PCR).

10. (Previously presented) A method according to claim 1, characterized in that the probe contains only one CpG.

11. (Previously presented) A method according to claim 1, characterized in that the probe contains several CpGs.

12. (Original) A method according to claim 11, characterized in that each probe for each CpG has a fluorescent label.

13. (Previously presented) A method according to claim 1, characterized in that the probe can be end labeled or internally labeled.

14. (Previously presented) A method according to claim 1, characterized in that the methylation information is determined by the change in fluorescence intensity during subsequent rounds of PCR.

15. (Previously presented) A method according to claim 1, characterized in that the sample DNA is only amplified by chosen PCR primers if a certain methylation state is present at a specific site in the sample DNA.

16. (Previously presented) A method according to claim1, characterized in that the sample DNA is only amplified if a certain methylation state was present at a specific site in the sample DNA, the sequence context of which is essentially complementary to one or more oligonucleotides or PNA oligomers which are additionally used in the PCR reaction.

17. (Previously presented) A method according to claim 1, characterized in that the amplification from the 3'-end of the probe is blocked by phosphorylation.

18. (Currently amended) A method according to claim 1 <u>characterized in</u> that a melting curve is generated at the end of the PCR to gather additional data.

19. (Previously presented) A method according to claim 1 wherein the fluorescent moiety is a fluorescein dye, a rhodamine dye, or a cyanine dye.

20. (Previously presented) A method according to claim 1 wherein the quencher moiety is a rhodamine dye.

21. (Previously presented) A method according to claim 1 wherein the deamination treatment of the DNA is performed with a bisulfite reagent.

22. (Currently amended) A method according to claim 1 ~~whereby~~ <u>wherein</u> the DNA sample is cleaved prior to deamination treatment with restriction endonucleases.

4

23. (Currently amended) A method according to claim 1 ~~whereby~~ wherein the DNA sample is isolated from mammalian sources ~~e.g. cell lines, blood, sputum, faeces, urine, cerebrospinal fluid, tissue embedded in paraffin, for example, ocular tissue, intestine, kidney, brain, heart, prostate, lung, chest or liver, histological slides and all possible combinations~~.

24. (Currently amended) ~~Use of a~~ A composition of pre-treated genomic DNA according to ~~claim 1~~ any one of the preceding claims for the determination of the methylation status of a corresponding genomic DNA.

25. (Currently amended) A diagnostic kit for the detection of the methylation of cytosine bases in genomic DNA samples according to any one of claims 1-23 and 26, comprising reagents for the selective deamination of cytosine bases in genomic DNA, one or more primers and labeled nucleotides for the amplification step, a detectable probe and optionally protocols or instructions for any one of the methods ~~according to one~~ of ~~the preceding~~ claims 1-23 and 26.

26. (New) The method as claimed in claim 23 wherein the DNA sample is isolated from a source selected from the group consisting of cell lines, blood, sputum, faeces, urine, cerebrospinal fluid, tissue embedded in paraffin, for example, ocular tissue, intestine, kidney, brain, heart, prostate, lung, chest or liver, histological slides and all possible combinations.